Therefore, our results suggest that induction of endogenous GDF15 is a compensatory mechanism to protect against the progression of NASH and that GDF15 could be an attractive therapeutic candidate for treatment of NASH and NASH-related metabolic deterioration. The gene discussed is GDF15; the disease is metabolic dysfunction-associated steatohepatitis.